- Home
- MBBC vs IGC Comparison
MBBC vs IGC Comparison
Compare MBBC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBBC | IGC |
|---|---|---|
| Founded | 1902 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 28.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | MBBC | IGC |
|---|---|---|
| Price | $14.00 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 1.9K | ★ 324.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.94 | $0.24 |
| 52 Week High | $14.64 | $0.50 |
Technical Indicators
Market Signals| Indicator | MBBC | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 49.85 |
| Support Level | $10.05 | N/A |
| Resistance Level | N/A | $0.32 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 66.14 | 38.57 |
Price Performance
Historical ComparisonAbout MBBC Marathon Bancorp Inc.
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.